Incyte expanded its AI partnership with Edison Scientific, paying $80 million upfront to broaden use of Edison’s platform across additional drug-discovery targets. The collaboration centers on integrating Edison’s AI scientist, “Kosmos,” into Incyte’s workflows and leveraging translational and clinical data. The companies said the initiative will embed predictive models into experimental design to improve consistency and decision quality, starting with high-impact use cases inside Incyte’s R&D. Edison’s approach is framed around continuous learning from data rather than one-off analyses. Incyte’s and Edison’s update reflects continued pharma adoption of AI systems that support hypothesis generation, target selection and translational modeling as companies seek to compress R&D timelines.